RBknee
Radiobotics ApS • Radiology • 08/27/2021
Device Purpose
RBknee is an automated software device utilizing machine learning and computer vision to analyze knee radiographs, providing objective measurements of joint space width and assessments of osteoarthritic features according to OARSI and Kellgren-Lawrence criteria. Its purpose is to aid medical professionals by offering standardized, quantitative data derived from CR or DX images to support the evaluation of knee osteoarthritis.
Summary
RBknee is a fully automated image processing software designed to assist medical professionals in evaluating knee radiographs for signs of osteoarthritis (OA). It processes computed (CR) or directly digital (DX) images, specifically standing, fixed-flexion anterior-posterior (AP) and posterior-anterior (PA) views of the knee. The software employs computer vision and machine learning algorithms, trained on a substantial dataset of medical images, to automatically analyze these radiographs. Its primary functions include measuring the minimum joint space width (JSW) and assessing the presence or absence of key osteoarthritic features such as sclerosis, joint space narrowing, and osteophytes, based on established OARSI (Osteoarthritis Research Society International) criteria. The device generates both visual and text reports. The visual report includes the original radiograph with overlays highlighting the minimum JSW and a table summarizing JSW measurements in millimeters, OARSI gradings for joint space narrowing, osteophytes, and sclerosis, and the Kellgren-Lawrence (KL) score for radiographic knee OA. The text report provides a narrative summary of these findings and an overall impression based on the KL score. RBknee does not interpret results but provides objective measurements and classifications. Clinical performance validation using the Osteoarthritis Initiative (OAI) database showed high sensitivity and specificity for detecting Kellgren-Lawrence status (0.88 sensitivity, 0.87 specificity), joint space narrowing (0.82 sensitivity, 0.87 specificity), osteophytosis (0.89 sensitivity, 0.78 specificity), and subchondral sclerosis (0.84 sensitivity, 0.87 specificity). JSW measurements demonstrated strong agreement with OAI data, with slopes near 1.00 and intercepts near zero for both medial and lateral compartments.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of RBknee's machine learning algorithms vary across different patient demographics (e.g., age, gender, BMI) not explicitly detailed in the OAI subset used for validation?; What was the inter-rater reliability of the ground truth OARSI and Kellgren-Lawrence grading performed by the two physicians with adjudication, and how might this variability impact the reported performance metrics of RBknee?; Can RBknee differentiate between early and advanced stages of specific OARSI features (e.g., osteophyte size, severity of sclerosis) beyond binary presence/absence, and if so, what is its accuracy for finer gradations?; What specific image features does the machine learning model prioritize when assessing for osteophytes, and how robust is it to variations in radiographic quality or technique?; How does RBknee's automated Joint Space Width measurement compare to manual or semi-automated methods in terms of both accuracy and time efficiency in a real-world clinical workflow?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly